I.CERAM |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.77 EUR | +8.45% |
|
-15.38% | -73.45% |
| Feb. 07 | I.Ceram: successful animal health implant | CF |
| Jan. 17 | I.Ceraam: up to 1.4 million in new financing | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2021 | 1.56M 1.7M | Sales 2022 | 1.43M 1.55M | Capitalization | 2.99M 3.24M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 | Net income 2022 | - 0 | EV / Sales 2021 | 4.44 x |
| Net Debt 2021 | 2.15M 2.33M | Net Debt 2022 | 1.8M 1.96M | EV / Sales 2022 | 3.35 x |
| P/E ratio 2021 |
-6.31
x | P/E ratio 2022 |
-3.18
x | Employees | 25 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 45.7% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +8.45% | ||
| 1 week | -15.38% | ||
| Current month | -56.98% | ||
| 1 month | -28.70% | ||
| 3 months | -76.67% | ||
| 6 months | -69.44% | ||
| Current year | -73.45% |
1 week
0.66
0.77
1 month
0.661.80
Current year
0.666.70
1 year
0.668.50
3 years
0.6635.20
5 years
0.6666.60
10 years
0.66239.80
| Managers | Title | Age | Since |
|---|---|---|---|
André Kérisit
CEO | Chief Executive Officer | 60 | 05-12-19 |
Eric Denes
CTO | Chief Tech/Sci/R&D Officer | - | 16-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Viviane Neiter
BRD | Director/Board Member | 68 | 14-09-17 |
| Director/Board Member | 66 | 19-04-15 | |
Bertrand Buguet
BRD | Director/Board Member | 56 | 14-09-17 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 0.77 | +8.45% | 30 |
| 24-05-17 | 0.71 | 0.00% | 9,790 |
| 24-05-16 | 0.71 | +7.58% | 395 |
| 24-05-15 | 0.66 | -27.47% | 512 |
| 24-05-14 | 0.91 | 0.00% | 0 |
Real-time Euronext Paris, May 20, 2024 at 03:48 am EDT
More quotes
I.Ceram specializes in the design, manufacture and marketing of orthopedic implants (metal, polymer and ceramic implants in porous alumina). The group provides prostheses for shoulder, spine, hip, tibia, ankle and foot as well as for osteosynthetic applications.
Net sales by source of income break down between sales of non-ceramic products (87%) and sales of ceramic products (13%).
France accounts for 70.3% of net sales.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -73.45% | 225K | |
| +10.11% | 127B | |
| -5.15% | 11.34B | |
| +6.07% | 9.11B | |
| +37.46% | 5.53B | |
| +8.53% | 3.45B | |
| -8.69% | 2.87B | |
| -6.38% | 2.1B | |
| -10.91% | 2.08B | |
| -23.21% | 1.78B |
- Stock Market
- Equities
- ALICR Stock
